{"id":"deferoxamine-mesylate-only","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Auditory toxicity"},{"rate":null,"effect":"Ocular toxicity"},{"rate":null,"effect":"Renal impairment"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Deferoxamine forms stable complexes with ferric iron (Fe³⁺), preventing iron from participating in harmful oxidative reactions and tissue damage. The drug-iron complex is then eliminated renally and hepatically, reducing iron overload in patients with conditions such as transfusion-dependent anemia or hemochromatosis. This mechanism protects organs from iron-induced fibrosis and dysfunction.","oneSentence":"Deferoxamine mesylate is an iron chelator that binds free iron and removes it from the body through urinary and fecal excretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:56.089Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Iron overload in patients with transfusion-dependent anemia"},{"name":"Secondary hemochromatosis"}]},"trialDetails":[{"nctId":"NCT06763055","phase":"PHASE3","title":"The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL","status":"RECRUITING","sponsor":"The George Institute","startDate":"2025-02-27","conditions":"Intracerebral Hemorrhage, Spontaneous Intracerebral Hemorrhage, Supratentorial Intracerebral Haemorrhage","enrollment":2000},{"nctId":"NCT06352632","phase":"PHASE3","title":"ACT-GLOBAL Adaptive Platform Trial for Stroke","status":"RECRUITING","sponsor":"The George Institute","startDate":"2024-09-26","conditions":"Stroke","enrollment":20000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1232,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Deferoxamine mesylate only","genericName":"Deferoxamine mesylate only","companyName":"The George Institute","companyId":"the-george-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Deferoxamine mesylate is an iron chelator that binds free iron and removes it from the body through urinary and fecal excretion. Used for Iron overload in patients with transfusion-dependent anemia, Secondary hemochromatosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}